Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues

Journal of Immunology

Volumn 160, Issue 4, 1998, Pages 1750-1758

  Valmori, Danila ^a,b   Fonteneau, Jean François ^c   Lizana, Concepción Marañón ^d   Gervois, Nadine ^c   Liénard, Danielle ^a,b   Rimoldi, Donata ^e   Jongeneel, Victor ^e   Jotereau, Francine ^c   Cerottini, Jean Charles ^b,e   Romero, Pedro ^b,e  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c INSERM   (France)

^d INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; LEUCINE; MELANOMA ANTIGEN; METHIONINE; PEPTIDE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, NEOPLASM; CELL LINE, TRANSFORMED; CELLS, CULTURED; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032520084     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Boon, T., J. C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337.
2. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281.
3. Coulie, P. G., F. Lehmann, B. Lethé, J. Herman, C. Lurquin, M. Andrawiss, and T. Boon. 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92:7976.
4. Robbins, P. F., M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and S. A. Rosenberg. 1996. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185.
5. Brichard, V. G., A. Van Pel, T. Wölfel, C. Wölfel, E. De Plaen, B. Lethé, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489.
6. Bakker, A. B. H., M. W. J. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005.
7. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
8. Wang, R. F., M. R. Parkhurst, Y. Kawakami, P. F. Robbins, and S. A. Rosenberg. 1996. Utilization of an alternative open reading frame of a normal gene generating a novel human cancer antigen. J. Exp. Med. 183:1131.
9. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
10. Coulie, P. G., V. Brichard, A. Van Pel, T. Wölfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, J. C. Renauld, and T. Boon. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
11. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
12. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257.
13. Spagnoli, G. C., C. Schaefer, T. E. Willimann, T. Kocher, A. Amoroso, A. Juretic, M. Zuber, U. Luscher, F. Harder, and M. Heberer. 1995. Peptide-specific CTL in tumor-infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: a study in an unselected group of HLA-A2.1 positive patients. Int. J. Cancer 64:309.
14. Jäger, E., H. Bernhard, P. Romero, M. Ringhoffer, M. Arand, J. Karbach, C. Ilsemann, M. Hagedorn, and A. Knuth. 1996. Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo: implications for tumor vaccines with melanoma associated antigens. Int. J. Cancer 66:162.
15. van Elsas, A., S. H. van der Burg, C. E. van der Minne, M. Borghi, J. S. Mourer, C. J. M. Melief, and P. I. Schrier. 1996. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201 binding peptides from the Melan-A/MART-1 self antigen. Eur. J. Immunol. 26:1683.
16. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wölfel, D. Liénard, V. Brichard, A. Van Pel, F. Jotereau, and J. C. Cerottini. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201 restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159:2366.
17. Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H. G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290.
18. Rammensee, H. G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
19. Ruppert, J., J. Sidney, E. Celis, R. T. Kubo, H. M. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929.
20. Valmori, D., D. Liénard, G. Waanders, D. Rimoldi, J. C. Cerottini, and P. Romero. 1997. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res. 57:735.
21. Gervois, N., Y. Guilloux, E. Diez, and F. Jotereau. 1996. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med. 183:2403.
22. van der Burg, S. H., M. J. W. Visseren, R. M. P. Brandt, W. M. Kast, and C. J. M. Melief. 1996. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156:3308.
23. Pogue, R. R., J. Eron, J. A. Frelinger, and M. Matsui. 1995. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. USA 92:8166.
24. Brasseur, F., D. Rimoldi, D. Liénard, B. Lethé, S. Carrel, F. Arienti, L. Suter, R. Vanwijck, A. Bourlond, Y. Humblet, A. Vacca, M. Conese, T. Lahaye, G. Degiovanni, R. Deraemaecker, M. Beauduin, X. Sastre, E. Salamon, B. Dréno, E. Jäger, A. Knuth, C. Chevreau, S. Suciu, J. M. Lachapelle, P. Pouillart, G. Parmiani, F. Lejeune, J. C. Cerottini, T. Boon, and M. Marchand. 1995. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer 63:375.
25. Nijman, H. W., J. G. Houbiers, M. P. Vierboom, S. H. van der Burg, J. W. Drijfhout, J. D'Amaro, P. Kenemans, C. J. Melief, and W. M. Kast. 1993. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23:1215.
26. Tsomides, T. J., E. B. Reilly, and H. N. Eisen. 1997. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having "self" sequences: autoimmune nature of the anti-melanoma CTL response. Int. Immunol. 9:327.
27. + cytotoxic T lymphocytes. J. Exp. Med. 181:363.
28. Romero, P., G. Eberl, J. L. Casanova, A. S. Cordey, C. Widmann, I. F. Luescher, G. Corradin, and J. L. Maryanski. 1992. Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. J. Immunol. 148:1871.
29. Chen, W., S. McCluskey, S. Rodda, and F. R. Carbone. 1993. Changes at peptide residues buried in the major histocompatibility complex (MHC) class I binding cleft influence T cell recognition: a possible role for indirect conformational alterations in the MHC class I or bound peptide in determining T cell recognition. J. Exp. Med. 177:869.
30. Madden, D. R., D. N. Garboczi, and D. C. Wiley. 1993. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75:693.
31. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, J. Ruppert, J. Sidney, M. F. Del Guercio, S. Southwood, R. T. Kubo, R. W. Chesnut, H. M. Grey, and F. V. Chisari. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
32. Bakker, A. B. H., S. H. van der Burg, R. J. F. Huijbens, J. W. Drijfhout, C. J. M. Melief, G. J. Adema, and C. G. Figdor. 1997. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type eptitope. Int. J. Cancer 70:302.
33. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:4749.
34. Vitiello, A., D. Marchesini, J. Furze, L. A. Sherman, and R. W. Chesnut. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1007.